Sugi Predict

Sugi Predict / Compounds / SCHEMBL10125852

SCHEMBL10125852

SCHEMBL10125852

Cc1ccc2nc(-c3ccc(-c4ccc(-c5nc6ccccc6nc5-c5ccccc5)cc4)cc3)oc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 11/20 0.62
▸ RAB9A P51151 11/20 0.62
▸ KDM4E B2RXH2 8/20 0.61
▸ SMN1; SMN2 Q16637 8/20 0.61
▸ HPGD P15428 7/20 0.61
▸ CASP3 P42574 2/20 0.61
▸ SENP8 Q96LD8 2/20 0.61
▸ SENP7 Q9BQF6 2/20 0.61
▸ SENP6 Q9GZR1 2/20 0.61
▸ POLB P06746 1/20 0.61
▸ ALDH1A1 P00352 8/20 0.59
▸ L3MBTL1 Q9Y468 2/20 0.59
▸ TDP1 Q9NUW8 2/20 0.58
▸ HSD17B10 Q99714 5/20 0.58
▸ MAPT P10636 4/20 0.58
▸ TP53 P04637 3/20 0.58
▸ CYP1A2 P05177 1/20 0.58
▸ CYP3A4 P08684 1/20 0.58
▸ CYP2D6 P10635 1/20 0.58
▸ CYP2C9 P11712 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10126036 0.97 NPC1 (0.65) NPC1RAB9AKDM4ESMN1; SMN2HPGD
SCHEMBL10315173 0.90 NPC1 (0.54) NPC1RAB9AKDM4ESMN1; SMN2HPGD
SCHEMBL10125853 0.89 KDM4E (0.78) NPC1RAB9AKDM4ESMN1; SMN2HPGD
SCHEMBL10315409 0.89 NPC1 (0.55) NPC1RAB9AKDM4ESMN1; SMN2HPGD
SCHEMBL436386 0.89 NPC1 (0.76) NPC1RAB9AKDM4ESMN1; SMN2HPGD
SCHEMBL23606717 0.86 GPR119 (0.49) NPC1RAB9AKDM4ESMN1; SMN2HPGD
SCHEMBL10126033 0.86 KDM4E (0.73) NPC1RAB9AKDM4ESMN1; SMN2HPGD
SCHEMBL10125924 0.86 TDP1 (0.60) NPC1RAB9AKDM4ESMN1; SMN2HPGD
SCHEMBL19601392 0.86 NPC1 (0.72) NPC1RAB9AKDM4ESMN1; SMN2HPGD
SCHEMBL10125862 0.85 SMN1; SMN2 (0.55) NPC1RAB9AKDM4ESMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119259-B2 Quinoxaline derivative, and light-emitting element and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-21 — — US disclosed
US-8119259-B2 Quinoxaline derivative, and light-emitting element and electronic device using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-21 — — US disclosed
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-04 — — US disclosed
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090140642-A1 Quinoxaline Derivative, and Light-Emitting Element and Electronic Device Using the Same NDUFA11, NDUFA9, NDUFA12 NPC1 4763/4885RAB9A 1141/4885KDM4E 2216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.